Phase 3 study on Multiple sclerosis (MS)2019-04-08T11:35:40+00:00

Project Description

Phase 3 study on Multiple sclerosis (MS)

Brief

Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system is directed against the central nervous system (brain, spinal cord and optic nerves). Current therapies reduce the outbreaks and improve patients quality of life, but they have insufficient efficacy to fight the progression of the disease. However, new promising therapeutic strategies could change the situation in the coming years.

It is in this perspective that R.G.L has been mandated by a biotechnology company to lead an international and competitive phase 3 study in Israel to prove the efficacy and the safety of a new drug.

Goals

  • Open Israel as a participating country in this trial, 
  • To complete international recruitment objectives in a short notice,

Want To Work With Us?

WE WILL BE HAPPY TO WORK WITH YOU.

Contact Us